Interleukin-6 activity in urine and serum in patients with bladder carcinoma.
To investigate the correlation between interleukin-6 and urothelial neoplasms, interleukin-6 activities in blood and urine samples of patients with bladder carcinoma were measured with a proliferation assay using an interleukin-6 dependent murine hybridoma clone, MH60.BSF2. A total of 43 patients and 15 normal volunteers were entered into this study. All of the patients were examined preoperatively and 26 were reexamined more than 6 days postoperatively to eliminate the effect of surgical injury on interleukin-6 secretion. The interleukin-6 titers in urine and serum increased in accordance with the progression of the tumor stage, and tumor removal induced a remarkable decrease in the titer of urinary interleukin-6. Although the interleukin-6-producing site has not been elucidated yet, our study suggests that interleukin-6 activity in bladder carcinoma patients may reflect the immunoreaction against the tumor in local urothelium.
Seguchi
T
T
Department of Urology, Osaka University Hospital, Japan.
Yokokawa
K
K
Sugao
H
H
Nakano
E
E
Sonoda
T
T
Okuyama
A
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002295:Carcinoma, Transitional Cell / Q000097:blood / Q000378:metabolism* / Q000473:pathology / Q000652:urine; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000097:blood / Q000378:metabolism* / Q000652:urine; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011184:Postoperative Period; D011300:Preoperative Care; D001749:Urinary Bladder Neoplasms / Q000097:blood / Q000378:metabolism* / Q000473:pathology / Q000652:urine
D015850:Interleukin-6